有效管理新陳代謝症候群之障礙

Barriers to Effective Management of Metabolic Syndrome

出版商	Decision Resources, Inc.
出版日期	2005年12月	商品編碼	38499
內容資訊	英文 Pages: 20
價格	本報告書已不再販售

簡介
目錄
相關商品

本報告已在2011年07月19日停止出版。

簡介

新陳代謝症候群治療市場從 2003 年的 97 億美元規模預計到 2013 年將成長到 128 億美元規模。該市場特別是歐洲市場還未全面發展，對於疾病的了解不多成為市場成長的障礙。

專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：麻薩諸塞州），針對有效管理新陳代謝症候群的障礙進行調查分析，經系統整理後出版報告書 "Barriers to Effective Management of Metabolic Syndrome" 。

本報告書內容包括：對新陳代謝症候群定義共識不足的問題、該問題對診斷造成的影響、研發中的藥劑所面對的課題、製藥產業今後的展望。共計 20 頁的內容綱要摘記如下：

簡介
對疾病定義共識的不足
診斷上的缺失
治療例子
償付環境
研發中的藥劑
新陳代謝症候群當做疾病的適切性

Decision Resources, Inc., forecasts that the market for metabolic syndrome therapies will increase from $9.7 billion in 2003 to $12.8 billion in 2013. This market has enormous untapped potential, especially in Europe, but several major barriers (e.g., a lack of consensus on the definition of the disease, underdiagnosis, poor management, difficulties in the licensing of new therapies, reimbursement restrictions) have constrained growth. In this report, we consider the problems resulting from the lack of a consensus definition of metabolic syndrome. We then examine how limited knowledge and inadequate screening have contributed to underdiagnosis of the disease. We review therapeutic options and assess the reimbursement environment for metabolic syndrome therapeutics. Further, we analyze the challenges that face drugs in development for this disorder and the consequences of a renewed debate over the validity of metabolic syndrome as a distinct disease. We conclude with an assessment of the outlook and implications for the pharmaceutical industry.

Overview

Lack of Consensus on Disease Definition

Underdiagnosis

Therapeutic Options

Reimbursement Environment

Drugs in Development

Validity of Metabolic Syndrome As a Distinct Disease

Outlook and Implications for the Pharmaceutical Industry